Positron Joint Venture Receives FDA Approval For AttriusTM Scanner Product Line

Main Category: MRI / PET / Ultrasound
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 08 May 2009 - 5:00 PDT

email to a friend   printer friendly   opinions  

Positron Corporation (OTCBB:POSC)(the "Company"), a cardiac molecular imaging solutions company, announced that the United States Food and Drug Administration (FDA) has approved Neusoft Positron Medical Systems 510(k) submission for its Attrius™ Positron Emission Tomography (PET) scanner product line developed by the Company and its joint venture with Neusoft Medical Systems based in Shenyang, China. Positron's Attrius™ product line was developed to provide physicians a state of the art cardiac PET molecular imaging system. The AttriusTM scanner comes complete with a feature set designed specifically for cardiac perfusion imaging such as a coronary artery disease software suite that includes; mercator projections, normal database comparison, coronary artery tree and distribution overlay map, rapid segmented attenuation correction, motion correction, and open acquisition architecture for today's challenging quantitative flow reserve imaging.

Joseph Oliverio, President of Positron states that "We believe that a significant market demand exists for a technology improvement in nuclear cardiology at an affordable cost of entry. Our Attrius device was specifically developed for cardiac molecular imaging and can provide patients with an accurate diagnosis resulting in cost savings to our healthcare system, the ability to track the efficacy of therapy, the potential for improved patient outcomes and help emergency room physicians see the result of a patient's chest pain without the need for an angiogram. This FDA approval allows us to immediately ramp up our sales & marketing efforts as we will offer the Attrius™ to the more than 4,000 cardiology offices and 3,000 target hospitals. The Company feels its Attrius™ PET scanner is the solution that thousands of cardiology groups are looking for to improve their bottom line, reduce healthcare costs and provide patients with a superior diagnosis of coronary artery disease."

Source
Positron

• Additional
• References
• Citations